New Phase 3 results offer renewed hope for patients and families, while highlighting the importance of timely and equitable access to innovative cancer treatments. 

October 24, 2026 – Toronto, ON – Melanoma Canada welcomes the promising results released by Merck and Moderna from their Phase 3 INTerpath-001 clinical trial, marking a significant advancement in the treatment of melanoma and an important milestone in personalized cancer care. Read the full news release from Merck and Moderna: https://www.merck.com/news/merck-and-moderna-will-present-results-from-landmark-phase-3-interpath-001-trial-for-intismeran-autogene-plus-keytruda-pembrolizumab-at-esmo-2026-presidential-symposium/  

The study found that combining a personalized mRNA cancer vaccine, intismeran autogene (V940), with the immunotherapy pembrolizumab (Keytruda) reduced the risk of melanoma recurrence or death by 42%, compared with pembrolizumab alone, in patients with high-risk melanoma whose cancer had been surgically removed. The combination also reduced the risk of distant metastasis or death by 38%. 

For patients and families living with melanoma, these results represent much more than scientific progress. They offer renewed hope for a future with fewer recurrences, fewer lives disrupted by cancer, and more time with loved ones. 

“Anyone who has faced a melanoma diagnosis knows that the fear of recurrence doesn’t simply disappear when treatment ends. It can follow patients and their families for years,” said Falyn Katz, CEO of Melanoma Canada. “These results offer meaningful hope that we are moving closer to a future where more people can live without their cancer returning. This is an incredibly exciting moment for the melanoma community.” 

Unlike traditional preventive vaccines, this investigational treatment is personalized to the unique genetic characteristics of each patient’s tumour, helping the immune system recognize and target cancer cells. It represents an important step toward more individualized cancer treatment. 

However, despite these encouraging results, it will likely be quite some time before this treatment becomes available to Canadian patients. The therapy remains investigational and must undergo regulatory review and approval before it can be offered as a standard treatment. Even following potential approval by Health Canada, additional health technology assessments, pricing negotiations, and provincial funding decisions may be required before patients can access it through the public healthcare system. These processes can take considerable time, and there is currently no confirmed timeline for Canadian availability. 

For patients facing melanoma today, this distinction matters. While the scientific progress is exciting, the uncertainty surrounding when new treatments will become accessible can be frustrating and emotionally difficult, particularly for those who have exhausted existing treatment options or are living with the fear of recurrence. 

“Scientific breakthroughs only change lives when patients can access them,” added Katz. “We want Canadians to share in the excitement surrounding these results, but we also need to be transparent that this is not a treatment patients will be able to access immediately. There is still a long road ahead, and for someone living with melanoma, time matters. We cannot allow unnecessary delays to stand between patients and potentially life-changing innovations.” 

Canada has made significant advances in melanoma treatment, but patients continue to face barriers to accessing emerging therapies, including regulatory timelines, public reimbursement decisions, and differences in access between provinces. 

Melanoma Canada calls on Canadian regulators, policymakers, healthcare professionals, and industry partners to begin preparing now for the potential introduction of personalized cancer vaccines, rather than waiting until regulatory approval to address access and implementation challenges. 

We must work collaboratively to ensure that, should this treatment receive approval, Canadian patients have timely and equitable access, regardless of where they live or their ability to pay. 

We also recognize the patients and families who participated in this clinical trial. Their willingness to contribute to research is helping shape the future of melanoma treatment for people around the world. 

Today, we celebrate an important scientific milestone, while recognizing that our work is far from over. Our commitment is to ensure that breakthroughs in melanoma research translate into meaningful improvements in the lives of Canadian patients. 

Learn more about Clinic Trials for Melanoma and Skin Cancer: https://melanomacanada.ca/healthcare-professionals/clinical-trial-finder/  

A melanoma & skin cancer diagnosis can be overwhelming. Melanoma Canada offers a wide variety of free services to support patients, families and caregivers through every step of their journey.  

View our support and resources page: https://melanomacanada.ca/support-and-resources/ or for direct support call 1.877.560.8035 x 108 or email support@melanomacanada.ca